QUANTUM AI MEETS MEDICINE ®
Our Journey
Over a decade, ago, our founder saw the need for a better use of data science to save lives. We began that journey researching and developing a big data analytics automated platform for HIV/AIDs and other infectious diseases. We were later selected by the National Institute of Health (NIH) to provide a commercially available, widely accessible data transfer tool equipped to improve case reporting on infectious diseases to local and international health organization.
Our Pipeline
We are designing and engineering molecular target to help accelerate drug discovery, and precision oncology.
We seek to not only transform cancer treatments, but utilize our technology platform to transform healthcare more broadly. Our AI drug discovery process goes through several distinct steps before target identification, designing a molecule and validations that can link to an onset and progression of a tumor. Our novel development techniques pave the way to life changing therapeutics for target discovery, validation and biomarkers that accelerate, improve, and disrupt the traditional drug discovery and development process. Collectively, these technologies will represent some of the most valuable biotechnologies ever created, and propel our efforts to continuously accelerate the average timeline and cost from discovery to commercialization. In doing so, allowing us to diagnose and help more patients around the world receive treatment, faster.Oncology | Quantum entanglements
Quantum Simulation & Predictive Analytics
Today, it takes on average more than 10 years for a treatment to be approved. That timeline can be even longer when the treatments aim to have long-term effects and vulnerabilities that lacks efficacy.
The discovery and development of new medicines requires a lengthy process. Scientists need to follow strenuous clinical trials over a long period of time to make sure the therapy is safe and effective.
Quantum – AI and machines will be able to inform regularity and therapeutic decision making regarding candidate drugs and their indications to help bring new medicines to the right patients faster than it is being done today.